Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
about
Interventions for dialysis patients with hepatitis C virus (HCV) infectionThe Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-AnalysisPegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center studyNanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Health care-associated hepatitis C virus infection.Hepatitis C and kidney transplantationEfficacy and safety of treatment of hepatitis C virus infection in renal transplant recipientsTreatment of hepatitis C virus infection in patients with end-stage renal disease.Hepatitis C virus and kidney: a strong association with different clinical aspects.Pegylated Interferon Mono-Therapy of Chronic Hepatitis C in the Dialysis Population: Systematic Review and Meta-Analysis.Hepatitis C infection and chronic renal diseases.Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient.Effects of pegylated interferon α on fibrinolytic parameters in patients with chronic hepatitis C.
P2860
Q24187826-61613E19-7C81-44BB-8713-C8BF4232AA0AQ28076929-2E20624E-0B22-4602-B816-D6A5E54B0AF5Q33434493-B2EB289F-1608-4B7A-8CDA-7753D82BB12BQ33559298-D53CAA6F-5A12-4F1A-8F7F-3DEF49D6699EQ34696503-1474F525-90B1-4393-8B6A-05B2442077A7Q35094769-713F22D3-38DB-4E31-8247-6297E6EC9999Q35653600-D38C59D7-8EE2-4D4C-A931-E6D59D992FEDQ37831965-0949279D-5F42-48EA-AF2C-FB46838F4698Q37899933-8231D38F-D6E8-4A9E-AF05-85C465FAD684Q38551615-E3A4711E-E148-4696-943A-EE7A8D75CE0FQ38552198-2467595F-41DE-45D4-AA7D-5C3D8A21DEC5Q39092977-5CD6A2DF-805F-4A44-B8CC-A044279CF1FCQ40832783-FF96AEE7-E41E-40C6-9968-B11551E0DA02Q42982413-0991A4A3-5140-4360-8C14-C6C2058B21D2Q44226369-CFAC6745-69D0-4F5B-A5E0-0CE804FFEE05Q50558980-B5CF7A1B-BD88-4CDC-A913-D3EE1BF656E8
P2860
Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of pegylat ...... ents with chronic hepatitis C.
@en
Efficacy and safety of pegylat ...... ents with chronic hepatitis C.
@nl
type
label
Efficacy and safety of pegylat ...... ents with chronic hepatitis C.
@en
Efficacy and safety of pegylat ...... ents with chronic hepatitis C.
@nl
prefLabel
Efficacy and safety of pegylat ...... ents with chronic hepatitis C.
@en
Efficacy and safety of pegylat ...... ents with chronic hepatitis C.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of pegylat ...... ents with chronic hepatitis C.
@en
P2093
Celal Ayaz
Mehmet Faruk Geyik
Mustafa Kemal Celen
Ugur Nedim Yuce
P2860
P304
P356
10.3748/WJG.14.255
P407
P577
2008-01-01T00:00:00Z